Brief: Sosei Heptares Says Will Explore Next Steps With Pfizer For Future Development Of Lotiglipron
26/06/2023 23:42
June 26 (Reuters) - Sosei Group Corp 4565.T :
* SOSEI HEPTARES PROVIDES UPDATE ON LOTIGLIPRON DEVELOPMENT
* WILL EXPLORE NEXT STEPS WITH PFIZER FOR FUTURE DEVELOPMENT
OF
LOTIGLIPRON
* IMPACT OF DISCONTINUATION IS THAT IT SHOULD NOT HAVE A
MATERIAL
IMPACT ON FULL YEAR 2023 FINANCIAL RESULTS
Source text for Eikon: ID:nGNXgRXPG
Further company coverage: 4565.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up